WEBINARS AND EVENTS Quarterly Molecular Tumor Board: Review targeted therapies and management options for breast cancer patients Speakers: Lincoln Nadauld MD, PhD, GI Medical Oncology Intermountain Health St George, UT Denise Yardley MD Breast Medical Oncologist Sarah Cannon Research Institute Nashville, TN Derrick Haslem MD Senior Medical Director Oncology Clinical Program Intermountain Health St George, UT Ben Kong PharmD Precision Medicine Specialist Knight Cancer Center Oregon Health Science University Portland, OR Date: 09/30/2025 Duration: 1 hour CEU: No The third session of our quarterly Molecular Tumor Board, in partnership with Clarified Health, focused on breast cancer, providing comprehensive insights from tumor genomic profiling and germline results. We will discuss critical biomarker results necessary for an informed discussion guiding treatment decisions. State-of-the-art and evidence-based assessment of Myriad Oncology™ tests and results Summarized, and de-identified, patient cases focusing on germline and tumor genomic landscapes Discussion of hereditary implications of genomic findings Prioritization of targeted therapy options based on genomic findings Hear from our Speaker Lincoln Nadauld MD, PhD, GI Medical Oncology Intermountain Health St George, UT Denise Yardley MD Breast Medical Oncologist Sarah Cannon Research Institute Nashville, TN Derrick Haslem MD Senior Medical Director Oncology Clinical Program Intermountain Health St George, UT Ben Kong PharmD Precision Medicine Specialist Knight Cancer Center Oregon Health Science University Portland, OR